Paradigm Biocapital Advisors LP
Q1 2023 13F-HR Holdings
Net value change ($000)
+203,273
(23.9%)
New positions
7
Sold out positions
5
Turnover %
29.9%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| KROS | 39,743 | NEW |
| ONC | 39,660 | NEW |
| Cerevel Therapeutics Holdings, Inc. | 38,907 | NEW |
| ARGX | 33,575 | 99.0% |
| BIIB | 31,076 | 47.0% |
| ACLX | 26,830 | 98.2% |
| XENE | 23,302 | NEW |
| INCY | 22,685 | 33.1% |
| Seagen Inc. | 20,299 | 55.2% |
| LEGN | 20,169 | 38.3% |
Top Reduces (Value $000, Stocks/ETFs)
| Horizon Therapeutics Public Ltd Co | -54,349 | -100.0% |
| AKRO | -33,129 | -100.0% |
| Karuna Therapeutics, Inc. | -20,870 | -100.0% |
| ARVN | -20,512 | -100.0% |
| Poseida Therapeutics, Inc. | -9,602 | -74.4% |
| VOR | -7,993 | -18.7% |
| Mirati Therapeutics, Inc. | -5,520 | -9.6% |
| ASND | -5,468 | -12.7% |
| PRTA | -4,519 | -100.0% |
| SNDX | -1,704 | -3.4% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|